


THE CLAIMS DEFINING THE INVENTION ARE AS FOLLOWS:

1. A compound of formula (I) or a pharmaceutically acceptable salt thereof;



wherein,

R₁ is H or C₁-C₆ alkyl; and

Hal is halogen.

2. A compound of claim 1 or a pharmaceutically acceptable salt thereof, wherein Hal is chloro or fluoro.

3. A compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein Hal is chloro.

4. A compound of any one of claims 1 to 3, or a pharmaceutically acceptable salt thereof, wherein R₁ is methyl.

5. A compound of any one of claims 1 to 3, or a pharmaceutically acceptable salt thereof, wherein R₁ is hydrogen.

6. A compound of any one of claims 1 to 4 or a pharmaceutically acceptable salt thereof, wherein R₁ is methyl in position 6 of the associated pyridine ring.

7. A compound of claim 1 or a pharmaceutically acceptable salt thereof, which is selected from

4-((2-chlorophenyl)amino)-6-(pyridin-2-ylamino)nicotinamide; and

4-((2-chlorophenyl)amino)-6-((6-methylpyridin-2-yl)amino)nicotinamide.

8. A pharmaceutical composition comprising a therapeutically effective amount of a compound according to any one of claims 1 to 7 and one or more pharmaceutically acceptable carriers.
9. A combination comprising a therapeutically effective amount of a compound according to any one of claims 1 to 7 or a pharmaceutically acceptable salt thereof and one or more therapeutically active co-agents.
10. A compound according to any one of claims 1 to 7 or a pharmaceutically acceptable salt thereof, for use as a medicament.
11. Use of a compound according to any one of claims 1 to 7 or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for the treatment of a disease or condition in a subject in need thereof, wherein JAK modulation plays a role or is implicated.
12. The use of claim 11, wherein the disease or condition is selected from allergic diseases, airway diseases, such as asthma and chronic obstructive pulmonary disease (COPD), rheumatoid arthritis, systemic onset juvenile idiopathic arthritis (SOJIA), gout, pemphigus vulgaris, idiopathic thrombocytopenic purpura, systemic lupus erythematosus, multiple sclerosis, myasthenia gravis, Sjögren's syndrome, thrombotic thrombocytopenic purpura, chronic autoimmune urticaria, atopic dermatitis, contact dermatitis, allergic rhinitis, atherosclerosis, type 1 diabetes, type 2 diabetes, inflammatory bowel disease, ulcerative colitis, morbus Crohn, pancreatitis, glomerulonephritis, Goodpasture's syndrome, Hashimoto's thyroiditis, Grave's disease, antibody-mediated transplant rejection (AMR), graft versus host disease, B cell-mediated hyperacute, and acute and chronic transplant rejection.
13. The use of claim 11, wherein the disease or condition is selected from asthma, chronic obstructive pulmonary disease (COPD), rheumatoid arthritis, systemic onset juvenile idiopathic arthritis (SOJIA), atopic dermatitis, contact dermatitis, allergic rhinitis, inflammatory bowel disease, ulcerative colitis, morbus Crohn, graft versus host disease.
14. The use of claim 11, wherein the disease or condition is chronic dermatitis, atopic dermatitis or psoriasis.